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Abstract 
Background: In the process of ABO‑incompatible (ABOi) organ transplantation, removal of anti‑A and/or B antibod‑
ies from blood plasma is a promising method to overcome hyperacute rejection and allograft loss caused by the 
immune response between anti‑A and/or B antibodies and the A and/or B antigens in the recipient. Although there 
are commercial columns to do this work, the application is still limited because of the high production cost.
Results: In this study, the PglB glycosylation pathway from Campylobacter jejuni was exploited to produce glycopro‑
tein conjugated with Escherichia coli O86:B7 O‑antigen, which bears the blood group B antigen epitope to absorb 
blood group B antibody in blood. The titers of blood group B antibody were reduced to a safe level without changing 
the clotting function of plasma after glycoprotein absorption of B antibodies in the plasma.
Conclusions: We developed a feasible strategy for the specific adsorption/removal of blood group antibodies. This 
method will be useful in ABOi organ transplantation and universal blood transfusion.
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Background
The ABO blood group system is the most important 
blood type system in humans. Blood type incompatibility 
means the exposure of A or B antigen to a person who 
has antibodies against these antigens [1]. These antibod-
ies act as haemagglutinins, which cause blood cells to 
clump and break apart, and can even cause death when 
large amounts of such cells are encountered after trans-
fusion or organ transplant. Removal of anti-A and/or B 
antibodies from plasma is a promising method to over-
come hyperacute rejection and allograft loss [2]. Several 
protocols have been employed to remove antibodies or 
antibody-producing cells in the process of ABOi organ 
transplantation [3], among which immunoadsorption 
has attracted more attention because of its specificity. 
The most commonly used immunoadsorbers are gly-
cosorb columns with A/B blood group antigens linked to 
a sepharosematrix [4, 5]. Unfortunately, A and B blood 
group antigens are difficult to acquire and immobilize [6].
At present, most A/B antigens used in glycosorb col-
umns are synthesized by chemical methods or enzymatic 
synthesis. One of the most difficult steps in the chemical 
synthesis of well-defined oligosaccharide antigens is the 
stereospecific formation of glycosidic linkages between 
monosaccharide units [7]. Enzymatic synthesis utilizing 
the corresponding glycosyltransferase is limited by the 
availability of enzymes and the cost of activated sugar 
donors [8]. Accordingly, it is necessary to find a low-cost 
and highly-effective method to produce A/B antigens to 
remove anti-A/B antibodies from plasma.
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The O-antigen in Escherichia coli (E. coli) O86:B7 
has been shown to possess high human blood group B 
activity because of the structural similarity between the 
O-antigen and human blood group B antigen epitope 
[9–11] (Fig. 1). Therefore, E. coli O86:B7 can be a poten-
tial cell factory of B antigens. We plan to obtain a type 
of glycoprotein loaded with this O-antigen that can be 
used to remove the A/B antibody from plasma. The oli-
gosaccharyl transferase PglB from Campylobacter jejuni 
(C. jejuni) can transfer a wide range of polysaccharides 
from undecaprenyl-pyrophosphate (Und-PP) linked pre-
cursors to the asparagine of the consensus sequence D/E-
X-N-Y-S/T (X, Y ≠ Proline) of the carrier protein in the 
periplasm [12, 13]. The N-glycosylation pathway from C. 
jejuni in recombinant E. coli has been shown to be a sim-
ple method for producing glycoprotein [12].
In our work, the N-glycosylation pathway of C. jejuni 
was used to produce glycoprotein conjugated with the 
O86 O-antigen (Fig. 2). The O86 O-antigen conjugated-
protein could adsorb anti-B antibody in the plasma, and 
the parameters of coagulation were not affected after the 
adsorbing process. Furthermore, it would have potential 
use in universal blood transfusion and may also be used 
in ABOi organ transplantation.
Results and discussion
The production and detection of MBPmut‑OPS (O86:B7) 
bioconjugates
To obtain glycoprotein loaded with OPS of O86:B7, PglB 
from C. jejuni was cloned into E. coli O86:B7 to transfer 
the O-antigen onto the protein, resulting in a kind of gly-
coprotein with OPS.
In E. coli, the OPS is transferred to lipid A by the WaaL 
enzyme to produce LPS. To effectively conjugate the OPS 
on a protein by PglB, the waaL gene was deleted from 
E. coli O86 using a λ-Red recombination system. The 
waaL gene deletion was confirmed using test primer pair 
t-waaL-F/t-waaL-R, which could amplify across the dele-
tion area. Furthermore, ladder straps were observed on 
the SDS-PAGE gel of LPS from wild E. coli O86, while 
no straps were observed in the lane of the LPS extracted 
from E. coli O86 ΔwaaL, which indicated that the LPS of 
E. coli O86 ΔwaaL had a low degree of polymerization 
(Fig. 3). Therefore, we successfully obtained a strain of E. 
coli O86:B7 without the waaL gene.
Fig. 1 The O‑antigen repeat unit structure of E. coli O86:B7. The 
human blood group B antigen epitope is labeled in a dashed box
Fig. 2 The scheme of the production of MBPmut‑OPS and its applica‑
tion
Fig. 3 Silver staining result of LPS. The silver staining was detected 
on 12 % gel. Line 1: LPS extracted from E. coli O86ΔwaaL; Line 2: LPS 
extracted from E. coli O86 wild type; M: protein Marker
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Maltose-binding protein (MBP) was selected as a car-
rier protein for OPS with B antigen activity. MBP is 
expressed in the periplasm of E. coli by the malE gene 
[14], which is generally used as a tag for expression and 
purification of foreign recombinant proteins [15] with a 
Amylose-Resin column. MBP without an N-glycosyla-
tion site was modified to MBPmut with four consensus 
sequences at the C terminal for loading with blood group 
B antigen epitope by cloned PglB in E. coli O86 ΔwaaL. 
The glycosylated MBPmut (i.e. MBPmut-OPS) and ungly-
cosylated MBPmut were purified from E. coli O86 ΔwaaL 
with or without the plasmid pACT3-PglB and identified 
by SDS-PAGE (Fig.  4a) and western blot using anti-His 
antibody (Fig. 4b), anti-MBP antibody (Fig. 4c) and anti-
O86 OPS antibody (Fig. 4d), respectively.
When probed using the anti-His and anti-MBP anti-
body, a ladder of bands appeared on the blot when 
MBPmut was expressed in E. coli O86 ΔwaaL with PglB 
(Fig. 4 lane 1), indicating that the protein was conjugated 
with multi-units of OPS (MBPmut-OPS), while unglyco-
sylated MBPmut expressed in E. coli O86 ΔwaaL without 
PglB showed only one band with a molecular weight of 
44  kDa, as expected (Fig.  4 lane 2). During the process 
of western blot, O86 antiserum instead of monoclonal 
anti-O86 antibody was used to determine the O-antigen 
activity of MBPmut-OPS. Therefore, nonspecific reaction 
might occur in form of the lightgray band on the western 
blot. These results were consistent with the finding that 
OPS had typical variability of chain length with different 
degrees of polymerization [16]. Furthermore, conjugation 
of OPS on MBPmut was confirmed by MALDI-TOF mass 
spectrometry. As expected, the molecular weight of MBP-
mut-OPS (47,898.93  Da) was higher than that of MBPmut 
(44,017.39 Da) (Additional file 1: Figure S1). The average 
number of OPS repeat units in purified MBPmut-OPS was 
four based on the molecular weight of one repeat unit of 
OPS (894 Da) and MBPmut (44017 Da). Moreover, 1.5 mg 
MBPmut-OPS was purified from 1  L of fermentation, 
which provided a way to obtain a large yield of glycopro-
teins using E. coli O86. We believe that the yield can be 
improved after optimizations such as culture conditions, 
fermentation method. Still, the cost of this approach to 
produce B-antigen absorption material is much lower 
than tradition method which includes enzymatic syn-
thesis of B-antigen saccharide using the corresponding 
glycosyltransferases because of the limited availability of 
enzymes, the high cost of activated sugar donors, etc.
Ability of MBPmut‑OPS conjugates to bind to blood group B 
antibody
An ELISA assay was conducted to measure the ability of 
MBPmut-OPS conjugates to bind with anti-A/B antibody. 
Unglycosylated MBPmut without blood group activity was 
used as a negative control. The MBPmut-OPS can be rec-
ognized by the anti-B antibody (Fig. 5b), but not by the 
anti-A antibody (Fig.  5a). No binding between unglyco-
sylated MBPmut and anti-A/B antibody was detected. 
These results suggested that MBPmut-OPS could bind 
anti-B antibody.
Specific absorption of blood group B antibody in the 
plasma
Based on the results of ELISA, MBPmut-OPS was applied 
to remove anti-B antibodies from blood group O and 
group A plasma as a B antigen. The removal rates of B 
antibody in plasma increased as increasing amounts of 
glycosylated MBPmut were added. The average blood 
group anti-B antibody titer of plasma samples of blood 
group O decreased from 64 to 4 (Fig. 6a) after treatment 
with MBPmut-OPS (320 μg/mL). A previous report indi-
cated that the antibody titer of plasma samples ≤8 is 
compliant with the restricting final titer for undergoing 
Fig. 4 SDS‑PAGE and western blot analysis of MBPmut and MBPmut‑
OPS from E. coli O86:B7. SDS‑PAGE analysis was carried out on 8 % gel 
(a). Western blot was detected by 8 % gel using anti‑His antibody (b), 
anti‑MBP antibody(c) and anti‑O86 antibody (d), respectively. Line 1: 
purified MBPmut‑OPS from E. coli O86:B7; Line 2: purified MBPmut; M: 
protein Marker
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surgery [17]. Analogously, upon evaluation of the plasma 
of blood group A, the titers of all samples decreased to a 
safe level of 4 after adsorption with a final concentration 
of 160 μg/mL MBPmut-OPS (Fig. 6b).
To investigate the effects of MBPmut-OPS on blood 
coagulation, the parameters of PT, APTT, TT, and Fib 
were detected within 4 h of blood withdrawn to citrate. 
None of the above parameters in the treated sample with 
MBPmut-OPS differed significantly from the control and 
levels remained normal (Fig.  6c). These results demon-
strated that MBPmut-OPS could absorb anti-B antibody 
effectively and did not affect the coagulation properties 
of the plasma. Thus, the purified glycoprotein with blood 
group B epitope has great potential for clinical applica-
tions. MBP with O-antigen of E. coli O86 could be used 
to remove anti-B antibody from group O or A in emer-
gency transfusions without strict matches. The produced 
MBPmut-OPS in E. coli O86 ΔwaaL will contribute sig-
nificantly to the development of a method for universal 
blood transfusion. Furthermore, for actual clinical appli-
cations, the endotoxin of the glycoprotein produced from 
E. coli cells should be removed to a safety level, which will 
be taken into consideration in our following study.
Conclusions
This study successfully glycosylated MBP with B antigen 
using a novel one-shot approach. In the system, large 
quantities of glycoproteins are produced and have great 
potential for further clinical development in many fields 
including ABOi organ transplantation and universal 
blood transfusion. In addition, glycoprotein with blood 
group antigens could also be used as research tools or 
alternative drugs for infection or other diseases associ-
ated with blood group antigens. A similar strategy could 
extend to blood group A antigen since anti-A agglutinins 
were reported to be absorbed by an A active E. freundii 
[18].
Methods
Bacterial strains, plasmids and growth condition
Escherichia coli O86:B7 (ATCC 12701) was obtained 
from American Type Culture Collection (Rockville, MD). 
Commercially available IgM monoclonal anti-B anti-
body (obtained from clone HEB-29) was purchased from 
Merck Millipore (Billerica, USA). All strains and plas-
mids used in this study were listed in Additional file  1: 
Table S1. All strains were grown in Luria–Bertani broth 
(LB) at 37 °C. E. coli DH5α and O86 were used for plas-
mids cloning and glycoprotein expression experiments, 
respectively. Ampicillin (100  μg/mL), 50  μg/mL kana-
mycin and 34 μg/mL chloramphenicol were added to the 
media for selection as needed. Plasmids pKD4, pKD46 
and pCP20 were used for the deletion of the gene cod-
ing for the O-polysaccharide ligase WaaL of E. coli O86. 
Plasmid pACT3 and pBAD24 were used for the expres-
sion of PglB and MBP protein, respectively.
Knockout of waaL gene of E. coli O86
The waaL gene of E. coli O86 was knocked out to obtain 
O86 ΔwaaL: FRT using λ-Red recombination system. 
Briefly, using plasmid pKD4 as template, the kanamycin-
resistant gene flanked by homologues of waaL gene was 
amplified by PCR with knockout primers. When induced 
by L-arabinose, plasmid pKD46 could express three 
recombinant proteins (Exo, Beta, Gam) of λ-prophage, 
which assisted the replacement of waaL gene with 
kanamycin-resistant gene. Subsequently, the kanamy-
cin-resistant gene was eliminated by FLP-promoted 
recombination system using plasmid pCP20 and the E. 
coli O86 ΔwaaL was obtained successfully. The knockout 
primers (k-waaL-F, k-waaL-R) and test primers (t-waaL-
F, t-waaL-R) used in the knockout experiments were listed 
in Additional file 1: Table S1. The extraction of LPS was 
carried out according to the instruction of LPS extraction 
kit (iNtRON Biotechnology, KOREA). The silver staining 
experiment was performed as reported previously [19].
Construction of recombinant plasmids
In order to ensure the successful glycosylation of MBP by 
PglB, the consensus sequence D-Q-N-A-T was repeated 
four times and inserted at the C terminal of MBP. 
Fig. 5 Binding of anti‑B antibody to MBPmut‑OPS from E. coli O86:B7. 
Antibody binding was assessed by ELISA in duplicate
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Overlap PCR was used to amplify the malEmut gene with 
primers malE-F, malE-R1, malE-R2 and malE-R3 (Addi-
tional file 1: Table S1). Restriction sites for Sal I and Hind 
III at their 5′ ends of primers were used for the insertion 
of the modified gene into the vector pBAD24, and thus 
the plasmid pBAD24-malEmut was obtained with a 6× 
His tag (i.e. N-HHHHHH-C) between Sma I and Sal I 
of pBAD24 (Induced by L-arabinose). Likewise, the pglB 
gene from C. jejuni NCTC 11168 was inserted between 
Sma I and Sal I of plasmid pACT3 (Induced by IPTG) 
and the plasmid pACT3-PglB was obtained.
Glycoprotein expression and purification
The recombinant plasmids pBAD24-malEmut and 
pACT3-PglB were co-transformed into E. coli O86 
ΔwaaL to obtain an engineering strain with the ability to 
produce MBPmut-OPS bioconjugates. Plasmid containing 
MBPmut gene was transformed into E. coli O86 ΔwaaL 
to produce unglycosylated MBPmut as a control. E. coli 
O86 ΔwaaL transferred with pBAD24-malEmut and 
pACT3-PglB was grown in 50 mL LB broth at 37 °C for 
16 h, with shaking. Cultures were then inoculated 1/100 
into 1 L TB broth and further grown at 37 °C with shak-
ing until OD600 reached 0.6. Subsequently, 0.1  % (w/v) 
L-arabinose and 50 μM IPTG were added to induce the 
expression of MBP and PglB, respectively. After further 
incubation at 28 °C for 6 h, 0.1 % (w/v) L-arabinose was 
added again for continuous induction of MBP.
After that, cells were pelleted by centrifugation at 
10,000 rpm for 15 min at 4 °C, and then resuspended in 
lysis buffer (50  mM PBS, 200  mM NaCl, 5  % glycerin, 
pH 7.4). The supernanant of cells after ultrasonic lysates 
was purified using pre-equilibrated Ni-nitrilotriacetic 
acid (NTA) columns under native conditions. Washing 
buffer (50 mM PBS, 200 mM NaCl, 5 % glycerin, 50 mM 
imidazole, and pH 7.4) and elution buffer (50 mM PBS, 
200 mM NaCl, 5 % glycerin, 250 mM imidazole, and pH 
7.4) were sequentially used. Fraction containing the puri-
fied glycoconjugate was collected and then desalted using 
centrifugal filter (Amicon® Ultra-15, Milipore) against 
Fig. 6 The titers of anti‑B antibodies and clotting parameters in the plasma before and after adsorption with MBPmut‑OPS. The titers of anti‑B 
antibodies in plasma samples of blood group O (a) and blood group A (b) before and after adsorption with different amount of MBPmut‑OPS were 
measured. The clotting parameters in plasma treated/pre‑treated with MBPmut‑OPS were detected with fully automatic blood coagulation analyzer 
(c). The hollow columns present the values of untreated plasma samples, while the filled ones denote the results of absorbed plasma samples. Error 
bars represent the standard deviation from three duplicates
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PBS (PH 7.4). The concentration of the proteins was 
measured with Bradford method.
Detection of purified glycoprotein
Western blotting was used to detect MBP and MBPmut-
OPS expression. Samples were separated on 8  % SDS-
denatured polyacrylamide gel and were then transferred 
onto nitrocellulose membrane. Membranes were blocked 
in 3  % BSA solution for 1  h at room temperature, and 
then were incubated with anti-hexahistine (anti-His) 
monoclonal antibody and anti-MBP monoclonal anti-
body (Beyotime Biotechnology, China), as well as anti-
O86 O-antigen polyclonal antibody (Tianjin Biochip 
Corporation, China), respectively overnight at 4  °C. 
The secondary antibodies with a horseradish peroxi-
dase (HRP) (Abcam, UK) were used subsequently. The 
image acquisition was finished by Flour ChemQ (Pro-
teinsimple, US). MALDI-TOF result was analyzed by the 
MALDI-TOF mass spectrometer (AXIMA Confidence, 
SHIMAZU, Japan) with sinapic acid as the matrix (50 % 
ACN, 50 % H2O, 0.1 % TFA).
Binding ability measurement of glycoprotein and anti‑B 
antibody
Polystyrene microtiter plates were coated by the purified 
proteins MBP/MBPmut-OPS from E. coli O86 at different 
concentration overnight at 4 °C. The plates were blocked 
with 2  % BSA in PBS buffer for 2  h at room tempera-
ture. After being washed three times with PBST (PBS, 
0.05 % Tween-20), the plates were incubated with anti-B 
antibody diluted to 1:20 for 2 h, or with anti-A antibody 
(1:20) as control. After washing, the secondary anti-
body goat anti-mouse IgM conjugated to HRP (1:20,000) 
(Abcam, UK) was added and maintained for 1 h. Finally, 
the TMB substrate was used to develop the signal and 
1  M HCl was used to terminate the reaction, and the 
OD was measured at 450 nm on Bio-Rad680 microplate 
reader (Hercules, California, USA).
Detection of the B antibody titer and coagulation 
parameters in the plasma
All blood samples, from 36 healthy people, were collected 
with citrate anticoagulation tubes, mixing, and were 
centrifuged at 1000g for 10 min to separate plasma. The 
plasma was divided two portions, one for the detection of 
B antibody titers, the other for coagulation analysis.
The B antibody titers in the plasma were measured with 
the polybrene test according to the instruction (Baso Bio-
logical Technology Corporation, Zhuhai, China). Briefly, 
twofold serial dilutions of plasma sample from 1:2 were 
made with normal saline for each tube. The same volume 
of 2 % type Bred blood cells were added to each tube and 
mixed thoroughly. Low ionic medium, polybrene reagent 
and resuspending were added subsequently and operated 
based on the instruction, and the smallest dilution which 
could still agglutinate erythrocyte was determined as the 
endpoint, and its reciprocal was considered as the titer of 
the sample plasma.
In order to detect the effects of proteins MBPmut-OPS 
on blood clotting function, coagulation parameters of 
the samples treated/pre-treated with MBPmut-OPS were 
measured with fully automatic blood coagulation ana-
lyzer ACL7000 (BECKMAN, USA).
Adsorption of blood group B antibody in the plasma
Aliquots of plasma samples of 800  μL were mixed with 
final concentration of 0, 80, 160 and 320 μg/mL MBPmut-
OPS, respectively. After incubation at room temperature 
for 1  h, the B antibody titer and clotting parameters in 
the plasma were detected as above methods.
Statistical analysis
The statistical analyses and figures were generated by 
GRAPHPAD PRISM software version 5.0. Data were 
shown as mean  ±  standard deviation (SD). The differ-
ence between two groups was compared by t test. For 
multiple comparisons, One-way ANOVA was used. A 
probability (P) value ≤ 0.05 was considered statistically 
significant.
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